1029: Skipping is Still a Common Problem with Radiofrequency Ablation of Small Renal Tumours

Abstract Purpose: This cohort aimed to evaluate the safety and efficacy outcomes of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) in a Western Australia tertiary hospital, Royal Perth Hospital (RPH), and potential associations between age, gender, tumour size, location, chronic kidney disease, comorbidities and local recurrence against existing benchmarks. Methods: We retrospectively analysed survival outcomes for patients with biopsy proven RCC treated by RFA at Royal Perth Hospital between 2009 and 2018. Complication data were gathered for all patients that underwent renal RFA along with 2- and 5-year recurrence-free (RFS) and compared the outcomes with data from previous studies. I confirm that all methods were carried out in accordance with relevant guidelines and regulations. Results: A total of 69 patients (73 procedures) were eligible for the study with biopsy-proven RCC had minimum 2-year follow-up. The RPH complication rate was 8.2 % (6/73) and local recurrence rate 10.9 % (8/73). Two-year RFS is 95.6% and Five-year RFS is 78.78% on a median 3.82-year follow-up (IQR 1.9-5.75). Conclusion: Radiofrequency ablation performed at our centre was found to be safe and effective with low complication rates and durable RFS in line with expectations from existing research. Our study demonstrated that radiofrequency ablation is an alternative modality of treatment for small renal tumours in patients unfit for surgical approach.

Download Full-text

Percutaneous radiofrequency ablation of renal tumours: 29-month mean follow-up results of 118 patients

Acta medica Lituanica ◽

10.6001/actamedica.v20i4.2820 ◽

2014 ◽

Vol 20 (4) ◽

pp. 219-228

Author(s):

Albertas Ulys ◽

Algirdas Žalimas ◽

Rūta Merkytė ◽

Sandra Selickaja ◽

Mantas Trakymas

Keyword(s):

Radiofrequency Ablation ◽

Thermal Effects ◽

Renal Tumors ◽

Percutaneous Radiofrequency Ablation ◽

Ultrasound Guided ◽

Kidney Tumors ◽

Renal Tumours ◽

Invasive Method ◽

The Mean

Background. Percutaneous radiofrequency ablation (RFA) is a minimally invasive method of treatment based on thermal effects. This retrospective study aimed to clarify percutaneous RFA of kidney tumors – performance, extremeness and 5-year survival in patients with small renal tumors in a single center. Materials and methods. Between September 2003 and December 2012, a total of 118 patients underwent percutaneous RFA of renal tumors. During more than 9 years period 144 RFA procedures were performed. Tumors were verified by biopsy. We used 3 RFA techniques: RFA under ultrasound control only (US), ultrasound guided RFA with CT navigation (US/CT) and ultrasound guided RFA with CT navigation, fiducial markers placed around the kidney tumor before the treatment (US/CT/FM). RFA electrodes were one and three. Patients were followed up regularly by CT with contrast enhancement. Results. The mean patient age was 68.72 years (range 28 to 86). The mean tumor size was 2.8 cm (range 1 to 5.4). The mean follow-up time was 29 months (1–111 months). Radical dependence on technical procedures: only US 39 (66.1%), US/CT 18 (94.7%), US/CT/FM 37 (92.5%), p = 0.001. Radical differences between using one and three electrodes: 39 (66.1%) and 55 (93.2%), p

Download Full-text